Clinical Trials Logo

Clinical Trial Details — Status: Not yet recruiting

Administrative data

NCT number NCT05340257
Other study ID # 215335
Secondary ID
Status Not yet recruiting
Phase Phase 2
First received
Last updated
Start date June 23, 2023
Est. completion date January 17, 2024

Study information

Verified date May 2023
Source GlaxoSmithKline
Contact US GSK Clinical Trials Call Center
Phone 877-379-3718
Email GSKClinicalSupportHD@gsk.com
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the pharmacokinetics, safety or tolerability through treatment emergent adverse event (TEAE) and to explore primary and secondary clinical response of treatment with Augmentin ES in pediatric population presenting with CAP and ABRS in Brazil.


Recruitment information / eligibility

Status Not yet recruiting
Enrollment 24
Est. completion date January 17, 2024
Est. primary completion date January 17, 2024
Accepts healthy volunteers No
Gender All
Age group 3 Months to 12 Years
Eligibility Inclusion Criteria: - The participant and/or parent(s)/legal guardian(s) are willing and able to comply with the study protocol. - In accordance with regional/local laws and regulations, - a. the parent(s)/legal guardian(s) has given signed informed, dated consent; and the participant has - b.given written assent, if applicable, to participate in the study (for participants between 7 to 12 years) - Age: Participant must be aged greater than or equal to (>=) 3 months to 12 years, of either gender. - Participants who are otherwise healthy and presenting with suspected CAP. - For participants clinically suspected of CAP, at least 3 of the following 4 criteria are applicable: - a) History of productive cough and/or shortness of breath. - b)Fever greater than (>)38.5 degree Celsius (?C) (Axillary temperature) - c) Tachypnea as defined by Respiratory rate (RR) >= 50 breaths/minute in children up to 11 months RR >= 40 breaths/minute in children from 12 months onwards - d) Chest X-Ray with shadow or lobar condensation, unilateral or bilateral. For participants of ABRS: - The participant and/or parent(s)/legal guardian(s) are willing and able to comply with the study protocol. - In accordance with regional/local laws and regulations, - a..The parent(s)/legal guardian(s) has given signed informed, dated consent; and the participant has - b. given written assent, if applicable, to participate in the study (for participants between 7 to 12 years). - Age: Participant must be between >=3 months to 12 years of either gender. - Participants who are otherwise healthy and presenting with suspected ABRS. - For participants of clinically suspected ABRS, the participants would be eligible if any of the following 2 of the 3 criteria stated below are met: - a.Children with purulent nasal discharge or daytime productive cough (which may worsen at night) or both persisting for 10 days or more without evidence of improvement. - b. Fever > 38.3?C (Axillary temperature) - c. Double sickness defined as initial improvement of symptoms and further worsening/ deterioration after 5 days. Exclusion Criteria: - Severe ABRS/CAP requiring hospitalization. - Currently receiving or has received more than one dose of systemic antibiotic therapy within one week prior to the initiation of the study. - A serious underlying disease as per clinician's judgment. - Human immunodeficiency virus (HIV) infection/or any other immunosuppressive condition - Pre-existing renal insufficiency (for example [e.g.], plasma creatinine > 1.5 times upper limit of normal range for age). - Pre-existing liver disease(s) and/or hepatic dysfunction. - Any pre-existing malignancy/any participants undergoing any kind of chemotherapy. - Evidence of leukopenia and/or thrombocytopenia. - History of previous hypersensitivity reaction to penicillins, cephalosporins or other Beta-lactam antibiotics. - History of amoxicillin-clavulanate associated cholestatic jaundice/hepatic dysfunction. - History of phenylketonuria or a known hypersensitivity to aspartame. - Received, within 48 hours of study entry, or is scheduled to receive during the study period, any medication which may alter bowel function. - Received, within 48 hours of study entry, or is scheduled to receive during the study period, any medication which may alter renal function like probenecid. - Participants who have chronic sinusitis (signs and symptoms lasting greater than 28 days prior to screening visit. - Significant abnormalities of the sinuses and any complications of ABRS. - Have concurrent streptococcal pharyngitis or acute otitis media (as the standard doses for both of these conditions is 10 days). - Any other infection or condition, which necessitates use of a concomitant systemic antimicrobial. - History of infectious mononucleosis. - History of pseudomembranous colitis. - Participants that are on warfarin therapy. - Receipt of an investigational compound (non-food and drug administration [FDA] and non-Brazil National Health Surveillance Agency [ANVISA] approved) or device within the previous 30 days or five half-lives, whichever is longer, preceding the first dose of study intervention or during the study. - Participants with symptoms suggestive of active Coronavirus disease 2019 (COVID-19) infection (that is (i.e.), fever, cough, etc.) - Participants with known COVID-19 positive contacts within the past 14 days. - Female participants who have attained menarche

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Augmentin ES
Amoxicillin and clavulanic acid in fixed dose combination will be administered

Locations

Country Name City State
n/a

Sponsors (1)

Lead Sponsor Collaborator
GlaxoSmithKline

Outcome

Type Measure Description Time frame Safety issue
Primary Absorption rate constant (Ka) of amoxicillin and clavulanic acid combination Up to 10 days
Primary Area under the serum concentration-time curve (AUC) of amoxicillin and clavulanic acid combination Up to 10 days
Primary Maximum serum concentration (Cmax) of amoxicillin and clavulanic acid combination Up to 10 days
Primary Clearance (CL) of amoxicillin and clavulanic acid combination Up to 10 days
Primary Volume of distribution (Vd) of amoxicillin and clavulanic acid combination Up to 10 days
Primary Terminal half-life (t1/2) of amoxicillin and clavulanic acid combination Up to 10 days
Secondary Number of participants with treatment emergent adverse events (TEAE) Up to Day 14
Secondary Number of participants achieving Primary Clinical Response Day 11 to Day 14
Secondary Number of participants achieving Secondary Clinical response Day 22 to Day 28
See also
  Status Clinical Trial Phase
Completed NCT04079790 - Pharmacokinetics of Gepotidacin Tablets in Adults and Adolescents Subjects Phase 1
Completed NCT01934205 - To Evaluate Plasma and Pulmonary Pharmacokinetics of GSK2140944 Phase 1
Not yet recruiting NCT02177721 - Clinical Benefit, Safety and PK of Raxibacumab in Subjects Exposed to Bacillus Anthracis Phase 4
Suspended NCT01132417 - In Vitro Activity of Tigecycline Among Key Bacterial Pathogens Exhibiting Multidrug Resistance N/A
Completed NCT00539994 - Retapamulin Ointment in Healthy Adults Nasally Colonized With Staphylococcus Aureus Phase 2
Completed NCT01610388 - A Study to Investigate the Safety, Tolerability and Pharmacokinetics of Oral and Intravenous GSK1322322 in Healthy Subjects Phase 1
Completed NCT01262885 - A Randomized, Single Blind, Placebo Controlled Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Single Oral Doses and Repeat Escalating Oral Doses of GSK2251052 in Healthy Adult Subjects Phase 1
Completed NCT00427141 - A Three-Part Study Of GSK580416 In Healthy Subjects Phase 1
Completed NCT04620486 - Effect of BPA on Anchor Antibiotic Continuity in the ED: Randomized Controlled Trial N/A
Recruiting NCT06451172 - Novel Antisense Oligonucleotide Eye Drops for Treating Antibiotic-Resistant Bacterial Keratitis Early Phase 1
Not yet recruiting NCT06440304 - Therapeutic Options for CRAB Phase 4
Completed NCT02292498 - Thermal Imaging to Diagnose and Monitor Suspected Bacterial Infections N/A
Completed NCT01587768 - WEUKBRE5555: IMI PROTECT(Work Package 2): Liver Injury & Antibiotics N/A
Withdrawn NCT01039610 - A Single Center Four Part Study in Healthy Adult Subjects to Evaluate: the Safety, Tolerability and Pharmacokinetics of a Single Oral Dose and Repeat Escalating Oral Doses of GSK945237; the Effect of Linezolid on Hematology Safety Parameters; and the Effects of GSK945237 and Moxifloxacin on QTc. Phase 1
Completed NCT00259909 - Observational Study Of An Electronic Questionnaire In Patients With Chronic Obstructive Pulmonary Disease (COPD) N/A
Completed NCT00828867 - Single Dose Escalation First Time in Human PK Study Phase 1
Completed NCT01431989 - Amoxicillin Bioequivalence Study Brazil - Fast Phase 1
Completed NCT02778672 - Thermal Imaging of the Lung on a Smartphone to Differentiate Bacterial From Non Bacterial Causes of Pneumonia N/A
Completed NCT00896558 - A Repeat Dose Escalation Study to Investigate the Safety, Tolerability and Pharmacokinetics of GSK1322322 in Healthy Subjects Phase 1
Completed NCT02045797 - Dose-Ranging Study of GSK2140944 in the Treatment of Subjects With Suspected or Confirmed Gram-Positive Acute Bacterial Skin and Skin Structure Infections Phase 2